The good times continue to roll for big cap device makers, with two companies doubling their market value, and not a single share price fall.
The market for minimally invasive aortic implants is sewn up – can a tiny private group find a way in?
The speediest device developer is Roche, but a look at companies’ strategies shows the perils of relying on bought-in tech.
A product sale nets the Australian company some much-needed cash, but its plan for the future is highly questionable.
Portico hits noninferiority, but safety looks doubtful. Abbott might want to prioritise a different approach.
Intuitive Surgical makes the most money per employee – but the title of “most improved” goes to Philips.
First-look data on Abbott’s tricuspid-focused MitraClip follow-on device are promising, but can TriClip emulate its predecessor’s success?
The battle for dominance of the transcatheter aortic valve market has shifted to new territory. And once again, Edwards Lifesciences is winning.
Transcatheter mitral valve replacement is wrenching the spotlight away from the repair devices that grabbed the headlines last summer.